New Scientist

Gene editing that spreads within the body could cure more diseases

The idea of self-amplifying gene editing is to get cells to pass on packages of CRISPR machinery to their neighbours, ...

Gene-editing therapy removes extra chromosome behind Down syndrome in a landmark lab study

Scientists have achieved a genetic feat once thought impossible: removing an entire extra human chromosome using gene-editing ...
Seeking Alpha

Crispr Therapeutics: Poised For A Major Turnaround

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...
Seeking Alpha

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...

Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline

CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an ...
C&EN

The Power to Edit DNA: CRISPR-Cas9 and Sickle Cell Disease

In December 2020, the New England Journal of Medicine published a paper titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, marking an exciting new chapter in the treatment of ...